The next focusIR Investor Webinar takes places on 14th May with guest speakers from Blue Whale Growth Fund, Taseko Mines, Kavango Resources and CQS Natural Resources fund. Please register here.
I do not post on here very often thesedays but as a continuing shareholder I must issue a rebuttal on the notion that £10 a share is a good place to start. The reason the company is valued at £50m is because there is not nearly enough buy in from shareholders as to the value at the commercialisation stage. Yet. At present AGL is not a commercial operation. It has a CE patent but clearly has designs on the big oppo that is the USA. Remarkable but true. AIM is no place for the partially unexplained so apart from the last two weeks, investors haven't had the weight of money to push this north of 80p. However, that will change. At some point there will be a distribution deal. AGL have 58m shares in issue. Given the size of the various markets that Parsotix will operate in, a net profit of £58m p.a. will be surpassed quite quickly. In these circumstances, and given that such a net profit (above) equates to £1 a share, do you really think it makes sense to pay only ten years earnings for the company? There are over six cancer diagnostic markets that P could operate in. So long as the KOL data comes in positive AND a distribution deal is announced, they won't be getting my shares for ten quid, FDA or no FDA.
If you are excited by the 27 jan RNS then I urge you to listen to to the presentation 2 days later by the CEO re the interims. It's a long listen at over 50 minutes however there is much to digest particularly as he reiterates how quickly we enter the clinical study/commercial stage.
On what basis? ( again not inflammatory, just think oeople need to substantiate why they think this?)
For me the trade price tells me that the vast majority are buys..
Why do you say £10 a share? What make you go that high ( which is extraordinary)? Not being inflammatory just curious
Another cosy arrangement for mr soukup
Next weeks results are stellar earnings. Do not sell at these prices and let others profit from you.
W/c 17.3.2014
...take a good look at TGS on the Oslo Stock Exchange, their annual earnings and their foothold in the Multi-Client market. This is a coat tail into the global market
So Mr Soukup has acquired a business for £1.86m as distinct from the £3.2m originally penned in September 2013. Whatever the merits of the reduction in consideration, this has the potential to be a viable business run alongside the existing PMSS business. They will operate separately within the group. This transaction reminds me of the OSS transaction in HYR, a company in administration acquired at knock down price that barely breaks even. There is something in there he likes obviously. Could it be the links to GoSciences existing customer base, Shell being one of them? All will be revealed over the next year. There's a lot to like about this plc.
In the absence if responses, I have investigated this myself and can confirm that the profit in question is $5m not £5m.
$36m turnover, how does that give £5m profit. These are two different currencies
I haven't seen your question until today and no I am not on drugs thank you. I was thinking a little ahead but on 17m shares earning 50 p a share that would require a profit of £8.5m. On 24m shares that would require a profit of £12m. That is the cost of the dilution. On a P/E ratio of 15 that would be a share price of £7.50. Obviously there is a long way to go but on £80 revenue in say 5 years it is not out of the question. My point was to answer the point on dilution not make forecasts about future prospects
..in one way in that for it to hit £7.50 in a year or two on 15 x earnings it will have to make a bit more profit than pre placing but maybe that is a price worth paying to kick off the growth phase. Let's face it there is a lot to organise to deliver the services to the clients
£18m on the slab. Order enquiries at record levels.
Where?
Thank you for coming back to me. Where can I find out what the free float is at various companies?
Will the Brewins and Can Accord s review their ratings now? This looks like a very steep fall for a stock which has done so well
£13 price target although they didnt say when
is there anyone who can tell me why the stock market is excited about an annoucment that actually didnt give much detail? Sorry im quite new to all this and saw this in a list of perfromers of the week